No connection

Search Results

LLY vs PLUR

LLY
Eli Lilly and Company
NEUTRAL
Price
$958.65
Market Cap
$858.01B
Sector
Healthcare
AI Confidence
85%
PLUR
Pluri Inc.
BEARISH
Price
$3.51
Market Cap
$35.3M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
LLY
41.7
PLUR
--
Forward P/E
LLY
22.78
PLUR
-1.85
P/B Ratio
LLY
32.33
PLUR
-2.4
P/S Ratio
LLY
13.16
PLUR
26.35
EV/EBITDA
LLY
27.08
PLUR
-2.58

Profitability

Gross Margin
LLY
83.04%
PLUR
40.63%
Operating Margin
LLY
44.9%
PLUR
-3285.86%
Profit Margin
LLY
31.67%
PLUR
0.0%
ROE
LLY
101.16%
PLUR
--
ROA
LLY
19.41%
PLUR
-50.6%

Growth

Revenue Growth
LLY
42.6%
PLUR
7.0%
Earnings Growth
LLY
51.4%
PLUR
--

Financial Health

Debt/Equity
LLY
1.65
PLUR
--
Current Ratio
LLY
1.58
PLUR
0.43
Quick Ratio
LLY
0.78
PLUR
0.39

Dividends

Dividend Yield
LLY
0.68%
PLUR
--
Payout Ratio
LLY
26.14%
PLUR
0.0%

AI Verdict

LLY NEUTRAL

LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.

Strengths
Strong profitability (31.7% margin)
Strong revenue growth of 42.6%
Strong ROE of 101.2%
Risks
High valuation with P/E of 41.7
Premium vs Graham Number ($123.85)
Weak financial trend (Piotroski F-Score: 3/9)
PLUR BEARISH

PLUR exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -2.40, indicating negative shareholder equity. The company is facing a severe liquidity crisis with a current ratio of 0.43, suggesting it cannot meet its short-term obligations. While recent quarterly earnings have beaten estimates, the operating margin of -3285.86% and a bearish technical trend (0/100) underscore a high risk of insolvency or significant shareholder dilution. The valuation is disconnected from fundamentals, trading at a high Price/Sales multiple of 26.35 despite sluggish revenue growth.

Strengths
Recent quarterly earnings beats (3 of last 4 quarters)
Positive YoY EPS growth (+71%)
Gross margin remains positive at 40.63%
Risks
Negative equity (P/B -2.40) indicating insolvency risk
Severe liquidity shortage (Current Ratio 0.43)
Catastrophic operating losses (-3285.86% margin)

Compare Another Pair

LLY vs PLUR: Head-to-Head Comparison

This page compares Eli Lilly and Company (LLY) and Pluri Inc. (PLUR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile